Related references
Note: Only part of the references are listed.The Exosomes Containing LINC00461 Originated from Multiple Myeloma Inhibit the Osteoblast Differentiation of Bone Mesenchymal Stem Cells via Sponging miR-324-3p
Yang Wu et al.
JOURNAL OF HEALTHCARE ENGINEERING (2022)
Protein arginine methyltransferase 5 has prognostic relevance and is a druggable target in multiple myeloma
A. Gulla et al.
LEUKEMIA (2018)
Drugging the lncRNA MALAT1 via LNA gapmeR ASO inhibits gene expression of proteasome subunits and triggers anti-multiple myeloma activity
Nicola Amodio et al.
LEUKEMIA (2018)
Dysregulation of EZH2/miR-138 axis contributes to drug resistance in multiple myeloma by downregulating RBPMS
Nasrin Rastgoo et al.
LEUKEMIA (2018)
Hypoxia-inducible KDM3A addiction in multiple myeloma
Sho Ikeda et al.
BLOOD ADVANCES (2018)
Epigenetic modifications in multiple myeloma: recent advances on the role of DNA and histone methylation
Nicola Amodio et al.
EXPERT OPINION ON THERAPEUTIC TARGETS (2017)
Genomic complexity of multiple myeloma and its clinical implications
Salomon Manier et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2017)
Lysine demethylase KDM3A regulates breast cancer cell invasion and apoptosis by targeting histone and the non-histone protein p53
S. Ramadoss et al.
ONCOGENE (2017)
HDAC3 regulates DNMT1 expression in multiple myeloma: therapeutic implications
T. Harada et al.
LEUKEMIA (2017)
KDM6B modulates MAPK pathway mediating multiple myeloma cell growth and survival
H. Ohguchi et al.
LEUKEMIA (2017)
Overexpression of EZH2 in multiple myeloma is associated with poor prognosis and dysregulation of cell cycle control
C. Pawlyn et al.
BLOOD CANCER JOURNAL (2017)
Inhibition of EZH2 triggers the tumor suppressive miR-29b network in multiple myeloma
Maria Angelica Stamato et al.
ONCOTARGET (2017)
UTX/KDM6A Loss Enhances the Malignant Phenotype of Multiple Myeloma and Sensitizes Cells to EZH2 inhibition
Teresa Ezponda et al.
CELL REPORTS (2017)
Dual Inhibition of EZH2 and EZH1 Sensitizes PRC2-Dependent Tumors to Proteasome Inhibition
Ola Rizq et al.
CLINICAL CANCER RESEARCH (2017)
Ricolinostat, the First Selective Histone Deacetylase 6 Inhibitor, in Combination with Bortezomib and Dexamethasone for Relapsed or Refractory Multiple Myeloma
Dan T. Vogl et al.
CLINICAL CANCER RESEARCH (2017)
EZH2 or HDAC1 Inhibition Reverses Multiple Myeloma-Induced Epigenetic Suppression of Osteoblast Differentiation
Juraj Adamik et al.
MOLECULAR CANCER RESEARCH (2017)
Evidence for a role of the histone deacetylase SIRT6 in DNA damage response of multiple myeloma cells
Michele Cea et al.
BLOOD (2016)
EZH2 Inhibition Blocks Multiple Myeloma Cell Growth through Upregulation of Epithelial Tumor Suppressor Genes
Henar Hernando et al.
MOLECULAR CANCER THERAPEUTICS (2016)
The Spectrum and Clinical Impact of Epigenetic Modifier Mutations in Myeloma
Charlotte Pawlyn et al.
CLINICAL CANCER RESEARCH (2016)
VANTAGE 095: An International, Multicenter, Open-Label Study of Vorinostat (MK-0683) in Combination With Bortezomib in Patients With Relapsed and Refractory Multiple Myeloma
David S. Siegel et al.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2016)
Histone demethylases in physiology and cancer: a tale of two enzymes, JMJD3 and UTX
Kelly Marie Arcipowski et al.
CURRENT OPINION IN GENETICS & DEVELOPMENT (2016)
Exploring the developmental mechanisms underlying Wolf-Hirschhorn Syndrome: Evidence for defects in neural crest cell migration
Erin L. Rutherford et al.
DEVELOPMENTAL BIOLOGY (2016)
Ricolinostat plus lenalidomide, and dexamethasone in relapsed or refractory multiple myeloma: a multicentre phase 1b trial
Andrew J. Yee et al.
LANCET ONCOLOGY (2016)
Therapeutic Targeting of miR-29b/HDAC4 Epigenetic Loop in Multiple Myeloma
Nicola Amodio et al.
MOLECULAR CANCER THERAPEUTICS (2016)
CBP/p300 acetyltransferase activity in hematologic malignancies
Ritika Dutta et al.
MOLECULAR GENETICS AND METABOLISM (2016)
MMSET/WHSC1 enhances DNA damage repair leading to an increase in resistance to chemotherapeutic agents
M. Y. Shah et al.
ONCOGENE (2016)
Discovery of selective small-molecule HDAC6 inhibitor for overcoming proteasome inhibitor resistance in multiple myeloma
Teru Hideshima et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2016)
The KDM3A-KLF2-IRF4 axis maintains myeloma cell survival
Hiroto Ohguchi et al.
NATURE COMMUNICATIONS (2016)
Bromodomain inhibition of the transcriptional coactivators CBP/EP300 as a therapeutic strategy to target the IRF4 network in multiple myeloma
Andrew R. Conery et al.
ELIFE (2016)
Histone deacetylase inhibitor panobinostat induces calcineurin degradation in multiple myeloma
Yoichi Imai et al.
JCI INSIGHT (2016)
Phase I study of carfilzomib, lenalidomide, vorinostat, and dexamethasone in patients with relapsed and/or refractory multiple myeloma
David H. Vesole et al.
BRITISH JOURNAL OF HAEMATOLOGY (2015)
Ricolinostat (ACY-1215) induced inhibition of aggresome formation accelerates carfilzomib-induced multiple myeloma cell death
Yuko Mishima et al.
BRITISH JOURNAL OF HAEMATOLOGY (2015)
Phase I/II study of the combination of panobinostat and carfilzomib in patients with relapsed/refractory multiple myeloma
Jesus G. Berdeja et al.
HAEMATOLOGICA (2015)
Phosphorylation-mediated EZH2 inactivation promotes drug resistance in multiple myeloma
Jiro Kikuchi et al.
JOURNAL OF CLINICAL INVESTIGATION (2015)
MMSET regulates expression of IRF4 in t(4;14) myeloma and its silencing potentiates the effect of bortezomib
Z. Xie et al.
LEUKEMIA (2015)
Class IIa HDAC inhibition enhances ER stress-mediated cell death in multiple myeloma
S. Kikuchi et al.
LEUKEMIA (2015)
Sound of silence: the properties and functions of repressive Lys methyltransferases
Chiara Mozzetta et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2015)
Transcriptional repression by the HDAC4-RelB-p52 complex regulates multiple myeloma survival and growth
Subrahmanya D. Vallabhapurapu et al.
NATURE COMMUNICATIONS (2015)
miR-29s: a family of epi-miRNAs with therapeutic implications in hematologic malignancies
Nicola Amodio et al.
ONCOTARGET (2015)
Phase I/II study of the combination of panobinostat and carfilzomib in patients with relapsed/refractory multiple myeloma
Jesus G. Berdeja et al.
HAEMATOLOGICA (2015)
Dysregulated Class I histone deacetylases are indicators of poor prognosis in multiple myeloma
Sridurga Mithraprabhu et al.
EPIGENETICS (2014)
c-Rel Regulates Ezh2 Expression in Activated Lymphocytes and Malignant Lymphoid Cells
Wen Hao Neo et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2014)
Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial
Jesus F. San-Miguel et al.
LANCET ONCOLOGY (2014)
Histone deacetylase 3 as a novel therapeutic target in multiple myeloma
J. Minami et al.
LEUKEMIA (2014)
Point mutation E1099K in MMSET/NSD2 enhances its methyltranferase activity and leads to altered global chromatin methylation in lymphoid malignancies
J. A. Oyer et al.
LEUKEMIA (2014)
Heterogeneity of genomic evolution and mutational profiles in multiple myeloma
Niccolo Bolli et al.
NATURE COMMUNICATIONS (2014)
Histone Methyltransferase MMSET/NSD2 Alters EZH2 Binding and Reprograms the Myeloma Epigenome through Global and Focal Changes in H3K36 and H3K27 Methylation
Relja Popovic et al.
PLOS GENETICS (2014)
PANORAMA 2: panobinostat in combination with bortezomib and dexamethasone in patients with relapsed and bortezomib-refractory myeloma
Paul G. Richardson et al.
BLOOD (2013)
SIRT6 Recruits SNF2H to DNA Break Sites, Preventing Genomic Instability through Chromatin Remodeling
Debra Toiber et al.
MOLECULAR CELL (2013)
Vorinostat or placebo in combination with bortezomib in patients with multiple myeloma (VANTAGE 088): a multicentre, randomised, double-blind study
Meletios Dimopoulos et al.
LANCET ONCOLOGY (2013)
MMSET stimulates myeloma cell growth through microRNA-mediated modulation of c-MYC
D-J Min et al.
LEUKEMIA (2013)
Epigenetic Regulation of Mouse Sex Determination by the Histone Demethylase Jmjd1a
Shunsuke Kuroki et al.
SCIENCE (2013)
Protein arginine methyltransferases and cancer
Yanzhong Yang et al.
NATURE REVIEWS CANCER (2013)
Preclinical activity, pharmacodynamic, and pharmacokinetic properties of a selective HDAC6 inhibitor, ACY-1215, in combination with bortezomib in multiple myeloma
Loredana Santo et al.
BLOOD (2012)
Cancer Epigenetics: From Mechanism to Therapy
Mark A. Dawson et al.
CELL (2012)
The Histone Deacetylase SIRT6 Is a Tumor Suppressor that Controls Cancer Metabolism
Carlos Sebastian et al.
CELL (2012)
Phase II trial of the pan-deacetylase inhibitor panobinostat as a single agent in advanced relapsed/refractory multiple myeloma
Jeffrey L. Wolf et al.
LEUKEMIA & LYMPHOMA (2012)
Histone methylation: a dynamic mark in health, disease and inheritance
Eric L. Greer et al.
NATURE REVIEWS GENETICS (2012)
Molecular mechanisms and potential functions of histone demethylases
Susanne Marije Kooistra et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2012)
A mechanistic rationale for MEK inhibitor therapy in myeloma based on blockade of MAF oncogene expression
Christina M. Annunziata et al.
BLOOD (2011)
Aberrant global methylation patterns affect the molecular pathogenesis and prognosis of multiple myeloma
Brian A. Walker et al.
BLOOD (2011)
The MMSET histone methyl transferase switches global histone methylation and alters gene expression in t(4;14) multiple myeloma cells
Eva Martinez-Garcia et al.
BLOOD (2011)
A high rate of durable responses with romidepsin, bortezomib, and dexamethasone in relapsed or refractory multiple myeloma
Simon J. Harrison et al.
BLOOD (2011)
Phase 2 Trial of the Histone Deacetylase Inhibitor Romidepsin for the Treatment of Refractory Multiple Myeloma
Ruben Niesvizky et al.
CANCER (2011)
Identification of 67 Histone Marks and Histone Lysine Crotonylation as a New Type of Histone Modification
Minjia Tan et al.
CELL (2011)
The Histone Methyltransferase and Putative Oncoprotein MMSET Is Overexpressed in a Large Variety of Human Tumors
Heidi Rye Hudlebusch et al.
CLINICAL CANCER RESEARCH (2011)
Distinct roles of GCN5/PCAF-mediated H3K9ac and CBP/p300-mediated H3K18/27ac in nuclear receptor transactivation
Qihuang Jin et al.
EMBO JOURNAL (2011)
NSD2 Links Dimethylation of Histone H3 at Lysine 36 to Oncogenic Programming
Alex J. Kuo et al.
MOLECULAR CELL (2011)
MMSET regulates histone H4K20 methylation and 53BP1 accumulation at DNA damage sites
Huadong Pei et al.
NATURE (2011)
The Polycomb complex PRC2 and its mark in life
Raphael Margueron et al.
NATURE (2011)
MEDICAL PROGRESS Multiple Myeloma
Antonio Palumbo et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
B cell homeostasis and plasma cell homing controlled by Kruppel-like factor 2
Rebecca Winkelmann et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2011)
Wolf-Hirschhorn syndrome candidate 1 is involved in the cellular response to DNA damage
Ildiko Hajdu et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2011)
Histone deacetylases are critical targets of bortezomib-induced cytotoxicity in multiple myeloma
Jiro Kikuchi et al.
BLOOD (2010)
The significance, development and progress of high-throughput combinatorial histone code analysis
Nicolas L. Young et al.
CELLULAR AND MOLECULAR LIFE SCIENCES (2010)
Regulation of the Histone Demethylase JMJD1A by Hypoxia-Inducible Factor 1 alpha Enhances Hypoxic Gene Expression and Tumor Growth
Adam J. Krieg et al.
MOLECULAR AND CELLULAR BIOLOGY (2010)
Chemical phylogenetics of histone deacetylases
James E. Bradner et al.
NATURE CHEMICAL BIOLOGY (2010)
Polycomb Target Genes Are Silenced in Multiple Myeloma
Antonia Kalushkova et al.
PLOS ONE (2010)
被撤回的出版物: Human SIRT6 Promotes DNA End Resection Through CtIP Deacetylation (Publication with Expression of Concern. See vol. 364, pg. 247, 2019) (Publication with Expression of Concern. See vol. 361, pg. 1322, 2018) (Retracted article. See vol. 364, pg. 247, 2019)
Abderrahmane Kaidi et al.
SCIENCE (2010)
The H3K27me3 demethylase JMJD3 contributes to the activation of the INK4A-ARF locus in response to oncogene- and stress-induced senescence
Karl Agger et al.
GENES & DEVELOPMENT (2009)
MMSET deregulation affects cell cycle progression and adhesion regulons in t(4;14) myeloma plasma cells
Jose L. R. Brito et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2009)
Role of Jhdm2a in regulating metabolic gene expression and obesity resistance
Keisuke Tateishi et al.
NATURE (2009)
Somatic mutations of the histone H3K27 demethylase gene UTX in human cancer
Gijs van Haaften et al.
NATURE GENETICS (2009)
The many roles of histone deacetylases in development and physiology: implications for disease and therapy
Michael Haberland et al.
NATURE REVIEWS GENETICS (2009)
Lysine Acetylation Targets Protein Complexes and Co-Regulates Major Cellular Functions
Chunaram Choudhary et al.
SCIENCE (2009)
The MMSET protein is a histone methyltransferase with characteristics of a transcriptional corepressor
Jotin Marango et al.
BLOOD (2008)
The multiple myeloma-associated MMSET gene contributes to cellular adhesion, clonogenic growth, and tumorigenicity
Josh Lauring et al.
BLOOD (2008)
The emerging field of dynamic lysine methylation of non-histone proteins
Jing Huang et al.
CURRENT OPINION IN GENETICS & DEVELOPMENT (2008)
Phase I trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) in patients with advanced multiple myeloma
Paul Richardson et al.
LEUKEMIA & LYMPHOMA (2008)
IRF4 addiction in multiple myeloma
Arthur L. Shaffer et al.
NATURE (2008)
SIRT6 is a histone H3 lysine 9 deacetylase that modulates telomeric chromatin
Eriko Michishita et al.
NATURE (2008)
MicroRNAs regulate critical genes associated with multiple myeloma pathogenesis
Flavia Pichiorri et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2008)
New nomenclature for chromatin-modifying enzymes
C. David Allis et al.
CELL (2007)
Histone demethylase JHDM2A is critical for Tnp1 and Prm1 transcription and spermatogenesis
Yuki Okada et al.
NATURE (2007)
Demethylation of H3K27 regulates polycomb recruitment and H2A ubiquitination
Min Gyu Lee et al.
SCIENCE (2007)
UTX and JMJD3 are histone H3K27 demethylases involved in HOX gene regulation and development
Karl Agger et al.
NATURE (2007)
The histone H3 lysine-27 demethylase Jmjd3 links inflammation to inhibition of polycomb-mediated gene silencing
Francesca De Santa et al.
CELL (2007)
Class IIa histone deacetylases: regulating the regulators
M. Martin et al.
ONCOGENE (2007)
Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets
Teru Hideshima et al.
NATURE REVIEWS CANCER (2007)
High-resolution profiling of histone methylations in the human genome
Artern Barski et al.
CELL (2007)
Genetic abnormalities and survival in multiple myeloma: the experience of the Intergroupe Francophone du Myelome
Herve Avet-Loiseau et al.
BLOOD (2007)
Sirtuins in aging and age-related disease
Valter D. Longo et al.
CELL (2006)
The histone deacetylase inhibitor LBH589 is a potent antimyeloma agent that overcomes drug resistance
Patricia Maiso et al.
CANCER RESEARCH (2006)
JHDM2A, a JmjC-containing H3K9 dernethylase, facilitates transcription activation by androgen receptor
Kenichi Yamane et al.
CELL (2006)
Anticancer activities of histone deacetylase inhibitors
Jessica E. Bolden et al.
NATURE REVIEWS DRUG DISCOVERY (2006)
Dual regulation of c-Myc by p300 via acetylation-dependent control of Myc protein turnover and coactivation of Myc-induced transcription
F Faiola et al.
MOLECULAR AND CELLULAR BIOLOGY (2005)
The polycomb group protein enhancer of zeste homolog 2 (EZH2) is an oncogene that influences myeloma cell growth and the mutant ras phenotype
PA Croonquist et al.
ONCOGENE (2005)
Small-molecule inhibition of proteasome and aggresome function induces synergistic antitumor activity in multiple myeloma
T Hideshima et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2005)
HDAC6 regulates Hsp90 acetylation and chaperone-dependent activation of glucocorticoid receptor
JJ Kovacs et al.
MOLECULAR CELL (2005)
Overexpression of transcripts originating from the MMSET locus characterizes all t(4;14)(p16;q32)-positive multiple myeloma patients
JJ Keats et al.
BLOOD (2005)
The deacetylase HDAC6 regulates aggresome formation and cell viability in response to misfolded protein stress
Y Kawaguchi et al.
CELL (2003)
NVP-LAQ824 is a potent novel histone deacetylase inhibitor with significant activity against multiple myeloma
L Catley et al.
BLOOD (2003)
Molecular sequelae of histone deacetylase inhibition in human malignant B cells
N Mitsiades et al.
BLOOD (2003)
A subset of multiple myeloma harboring the t(4;14)(p16;q32) translocation lacks FGFR3 expression but maintains an IGH/MMSET fusion transcript
M Santra et al.
BLOOD (2003)
In multiple myeloma, t(4;14)(p16;q32) is an adverse prognostic factor irrespective of FGFR3 expression
JJ Keats et al.
BLOOD (2003)
Gene expression profiling of human plasma cell differentiation and classification of multiple myeloma based on similarities to distinct stages of late-stage B-cell development
FH Zhan et al.
BLOOD (2003)
Global gene expression profiling of multiple myeloma, monoclonal gammopathy of undetermined significance, and normal bone marrow plasma cells
FH Zhan et al.
BLOOD (2002)
Aggresomes, inclusion bodies and protein aggregation
RR Kopito
TRENDS IN CELL BIOLOGY (2000)
Share Paper
